Contemporary ideas about pathophysiological mechanisms of immunity destruction in the preclinical stage of type 1 diabetes

Authors

  • Popova V. V. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kiev, Ukraine
  • Zak K. P. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kiev, Ukraine
  • Tron’ko N. D. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of NAMS of Ukraine», Kiev, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2019.3.18

Keywords:

immune system, type 1 diabetes mellitus

Abstract

The results of own studies on the role of the immune system in mechanisms for development of type 1 diabetes mellitus (T1DM) in humans that have been performed for 20 years in 612 normoglycemic children of Ukraine with a burden heredity which are positive and negative against pancreatic islet autoantibodies (OAA) are summarized in the article according to the program of the IPDM. There were confirmed data that the high titre of two (especially IA-2A and GADA) and more OAA is a reliable biomarker for diagnosing the presence of preclinical asymptomatic stage of T1DM and predicting its appearance in advance (sometimes for years) in still healthy people. The preclinical stage in OAA-positive children is characterized by moderate neutrophilopenia, monocytosis with a change in their ultrastructure, a decrease in the absolute number of CD3 + T, CD4 + T and CD8 + T lymphocytes and CD56 + cells. In the subpopulation of CD4 + T cells, a disorder of the submicroscopic organization of Holl's bodies is noted. At the same time, there is an increase in the level of proinflammatory cytokines IL-1α, IL-1β, IL-6 and TNFα, as well as chemokines IL-8 and IL-10 and simultaneous decrease of immunoregulatory cytokines IL-4 and IL-10. The obtained data indicate that already in the preclinical stage of T1DM immunity is significantly impaired in the body of normoglycemic children, that is consistent with the recently expressed opinion that the T1DM should be diagnosed not only when most of the beta cells have been destroyed, but in the stage of pre-diabetes, when immune intervention preventing the progression of the disease is still possible.

References

IDF. Diabetes Atlas. 8th Edition. 2017.

Tron’ko MD. Endokrynolohiya 2018; 23(1): 5-15.

American Diabetes Association. Diabetes Care 2018; 41(5): 917-928. https://doi.org/10.2337/dci18-0007.

Chiang JL, Maahs DM, Garvey KC, et al. Diabetes Care 2018; 41(9): 2026-2044. https://doi.org/10.2337/dci18-0023.

Zak KP, Popova VV. Diabet. Ozhyrinnya Metabolichnyy syndrome 2015; 6(IV): 31–44.

Bingley PJ, Wherrett DK, Shultz A, et al. Diabetes Care 2018; 41(4): 653-661. https://doi.org/10.2337/dc17-0806.

Bonifacio E, Mathieu Ch, Nepom GT, et al. Diabetologia 2017; 60(1): 35-38. https://doi.org/10.1007/s00125-016-4144-8.

Ziegler AG, Bonifacio E, Powers AC, et al. Diabetes 2016; 65(11): 3233-3239. https://doi.org/10.2337/db16-0687.

Endesfelder D, Zu Castell W, Bonifacio E, et al. Diabetes 2019; 68(1): 119-130. https://doi.org/10.2337/db18-0594.

Grubb AL, McDonald TJ, Rutters F, et al. Diabetes Care 2019; 42(2): 208-214. https://doi.org/10.2337/dc18-0431.

Regnell SE, Lernmark Е. Diabetologia 2017; 60(8): 1370-1381. https://doi.org/10.1007/s00125-017-4308-1.

Xu P, Krischer JP. Diabetes Care 2016; 39(6): 1036-1044. https://doi.org/10.2337/dc15-2292.

Ziegler AG, Bonifacio E. Diabetologia 2012; 55(7): 1937-1943. https://doi.org/10.1007/s00125-012-2472-x.

Insel RA, Dunne JL, Atkinson MA, et al. Diabetes Care 2015; 38(10): 1964-1974. https://doi.org/10.2337/dc15-1419.

Sosenko JM, Skyler JS, DiMeglio LA, et al. Diabetes Care 2015; 38(2): 271-276. https://doi.org/10.2337/dc14-1813.

Nathan BM, Boulware D, Geyer S, et al. Diabetes Care 2017; 40(11): 1494-1499. https://doi.org/10.2337/dc17-0916.

Atkinson MA, von Herrath M, Powers AC, Clare-Salzler M. Diabetes Care 2015; 38(6): 979-988. https://doi.org/10.2337/dc15-0144.

Tron’ko ND, Popova VV, Zak KP, Man’kovsky BN. Endokrinolohya 2010; 15(2): 180-191.

Popova V, Zak K, Gruzov M, et al. Diabetologia 2006; 49(1): 280-281.

Zak KP, Tron’ko ND, Popova VV, Butenko AK. Diabetes. Immunity. Cytokines, Kyiv, 2015: 485 p.

Zak KP, Popova VV. Mizhnar Endokrynol Zhurn 2016; 7(79): 11-21.

Popova VV, Zak KP, Mel’nichenko SV, et al. Endokrynolohya 2018: 23(2): 109-121.

Mathieu C, Lahesmaa R, Bonifacio E, et al. Diabetologia 2018 Nov; 61(11):2252-58. https://doi.org/10.1007/s00125-018-4726-8.

Zak KP, Afanas’eva VV, Hruzov MA. Microcirculation and its age-related changes: II mizhnarodnoya konferentsiya, Kyiv, 2002: 118-119.

Valle A, Giamporcaro GM, Scavini M, et al. Diabetes 2013; 62(6): 2072-2077. https://doi.org/10.2337/db12-1345.

Salami F, Lee HS, Freyhult E, et al. Diabetes 2018; 67(11): 2329-2336. https://doi.org/10.2337/db18-0355.

Zak KP. Mizhnar Endokrynol Zhurn 2016; 2(74): 130-139.

Zak KP, Popova VV, Grusov MA, et al. Endokrynolohya 2017; 22(3): 201-210.

Haller MJ, Gitelman SE, Gottlieb PA, et al. J Clin Invest 2015; 125(1): 448-455. https://doi.org/10.1172/JCI78492.

Schneider D, Von Herrath MG. Diabetologia 2014; 57(10): 2009-2018. https://doi.org/10.1007/s00125-014-3340-7.

Wang Y, Xiao Y, Zhong L, et al. Diabetes 2014; 63(12): 4239-4248. https://doi.org/10.2337/db14-0480.

Afanas’yeva VV, Zak KP, Yefimov AS. Terapevt. Arkh 1988; 60(5): 95-98.

Cipolletta C, Ryan KE, Hanna EV, Trimble ER. Diabetes 2005; 54(9): 2779-2786.

Molvig J, Pociot F, Baek L, et al. Scand J Immunol 1990; 32(3): 297-311. https://doi.org/10.1111/j.1365-3083.1990.tb02924.

Devaraj S, Glaser N, Griffen S, et al. Diabetes 2006; 55(3): 774-779.

Bradshaw EM, Raddassi K, Elyaman W, et al. J Immunol 2009; 183(7): 4432-4439. https://doi.org/10.4049/jimmunol.0900576.

Santos AS, Chevillard C, Gonfinetti NV, et al. Diabetologia 2018; 61(1): 304. https://doi.org/10.1016/j.gene.2012.09.090.

Viisanen T, Ihantola EL, Nanto-Salonen K, et al. Diabetes 2017; 66(2): 437-447. https://doi.org/10.2337/db16-0714.

Long SA, Thorpe J, DeBerg HA, et al. Sci Immunol 2016; 1(5): aai7793. https://doi.org/10.1126/sciimmunol.aai7793.

Heninger AK, Eugster A, Kuehn D, et al. Sci Transl Med 2 017; 9 (378). p ii: e aaf8848. https://doi.org/10.1126/scitranslmed.aaf8848.

Lee Yong-ho, Kim So Ra, Han Dai Hoon, et al. Diabetes 2018; 68(1): db171218. https://doi.org/10.2337/db17-1218.

Gall. Am J Med Sci 1936; 191: 380-388.

Khomenko BM, Gruzov MA, Shlyakhovenko VS, Zak KP. Fiziol Zhurn 1989; 35 (5): 31-38.

Hussain MJ, Peakman M, Gallati H, et al. Diabetologia 1996; 39(1): 60-69.

Mandrup-Poulsen T. Diabetes 2 014; 6 3(6): 1 833-1835. https://doi.org/10.2337/db14-0371.

Mandrup-Poulsen T. Diabetologia 1996; 39(4): 1005-1029.

Chen YG, Cabrera SM, ,Jia S, et al. Diabetes 2014; 63(11): 3960-3973. https://doi.org/10.2337/db14-0214.

Zak KP, Popova VV. Mizhnar Endokrynol Zhurn 2018; 14(5): 92-99. https://doi.org/10.22141/2224-0721.14.5.2018.142690.

Aggarwal BB, Gupta SC, Kim JH. Blood 2012; 119(3): 651-665. https://doi.org/10.1182/blood-2011-04-325225.

Muz NM, Popova VV, Orlenko VL, et al. Diabetologia 2018; 61(1): 293.

Fores JP, Crisostomo LG, Orii NM, et al. Cell Immunol 2018; 324: 8-13. https://doi.org/10.1016/j.cellimm.2017.11.005.

Delves PJ, Roitt IM. New Engl J Med 2000; 343(1): 37-49.

Lo Hui-Chen, Lin Su-Chen, Wang Yu-Mei. Clin Biochem 2004; 37(8): 666-672. https://doi.org/10.1016/j.clinbiochem.2004.02.002.

Hedman M, Faresjo M, Axelsson S. Diabetologia 2007; 50(1): 191.

Tree TI, Lawson J, Edwards H, et al. Diabetes 2010; 59(6): 1451-1460. https://doi.org/10.2337/db09-0503.

Hummel S, Beyerlein A, Tamura R, et al. Diabetes Care 2017; 40(3): 398-404. https://doi.org/10.2337/dc16-1624.

Adel Abdel-Moneim, Heba H Bakery, Gamal Allam. Biomed Pharmacother 2018; 101: 287-292. https://doi.org/10.1016/j.biopha.2018.02.103.

Downloads

Published

2019-08-28

How to Cite

Popova, V. V., Zak, K. P., & Tron’ko, N. D. (2019). Contemporary ideas about pathophysiological mechanisms of immunity destruction in the preclinical stage of type 1 diabetes. Problems of Endocrine Pathology, 69(3), 136-143. https://doi.org/10.21856/j-PEP.2019.3.18